Million-yuan CAR-T cancer drug included in basic medical insurance for the first time, with patients' out-of-pocket costs reduced to under 100,000 yuan.

The million-yuan CAR-T anti-cancer therapy has achieved a historic breakthrough: JW Therapeutics' relma-cel injection has been included in basic medical insurance for the first time, and after reimbursement, patients' out-of-pocket costs will drop to less than 100,000 yuan. The core reason this "sky-high-priced drug" could enter basic medical insurance with a substantial price cut is that key raw materials have achieved domestic production, which can significantly reduce production costs.